Quantcast

Latest National Institute of Neurological Disorders and Stroke Stories

8771c29aa2d4fca90276ba922b8d510b
2009-11-03 09:32:14

Researchers have developed an improved version of an enzyme that degrades the dense scar tissue that forms when the central nervous system is damaged. By digesting the tissue that blocks re-growth of damaged nerves, the improved enzyme "“ and new system for delivering it "“ could facilitate recovery from serious central nervous system injuries. The enzyme, chrondroitinase ABC (chABC), must be supplied to the damaged area for at least two weeks following injury to fully degrade...

2009-11-02 15:05:00

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers. The work is the outcome of basic research...

2009-10-22 11:58:00

NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. a privately-held biotechnology company with a portfolio of novel targeted therapies for oncology and neurodegenerative disorders, based in New York City, today announced that it has been awarded a Phase I grant from the National Institute of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) for the Development Of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma. The grant of up...

2009-10-15 06:00:00

BOSTON, Oct. 15 /PRNewswire/ -- Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS). The five-year cooperative agreement encompasses pre-clinical drug development up to the time of an Investigational New Drug...

2009-10-12 16:29:28

Data collected in 1980s points to method to predict course of disease Parkinson disease progresses more slowly in patients who have higher levels of urate, a chemical that at very high level is associated with gout, scientists have found. While it's unknown whether the high levels actually somehow protect patients or simply serve as a marker of protection, the finding supports the idea that patients and doctors may one day be able to better predict the course of the illness. The study, led by...

2009-10-12 16:19:34

Individuals with Parkinson's disease who have higher levels of a metabolite called urate in their blood and in cerebrospinal fluid (CSF) have a slower rate of disease progression, according to a study funded by the National Institutes of Health. A clinical trial is under way to examine the safety and potential benefits of supplemental urate elevation for recently diagnosed Parkinson's patients who have low urate levels. Investigators demonstrated the link with urate by mining a repository of...

2009-07-02 08:00:00

EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research...

2009-01-20 10:55:00

People who received a mild electrical current to a motor control area of the brain were significantly better able to learn and perform a complex motor task than those in control groups. The findings could hold promise for enhancing rehabilitation for people with traumatic brain injury, stroke and other conditions. The study is presented in the January 20, 2009 early online edition of the Proceedings of the National Academy of Sciences, and was conducted by researchers at the National...

2009-01-07 08:33:45

Deep brain stimulation to help reduce tremors and other symptoms in people with Parkinson's disease has some serious side effects, a U.S. study finds. These include infection at the surgical site and cognitive decline, the study of 225 advanced Parkinson's patients at seven U.S. Veterans Affairs hospitals and six university medical centers found. The study, published in Wednesday's Journal of the American Medical Association, also found benefits to the procedure, in which electrodes are...

2008-10-17 12:00:25

Bolder BioTechnology has obtained a $1.6 million Phase II continuing renewal small business innovation research grant from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health. Receipt of the entire grant award is contingent upon the achievement of certain research milestones. George Cox, president of Bolder BioTechnology, said: "We are grateful to receive continued support from the National Institute of Neurological Disorders and Stroke (NINDS)...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related